Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 28
Filtrar
1.
J Drugs Dermatol ; 22(12): e51-e52, 2023 12 01.
Artigo em Inglês | MEDLINE | ID: mdl-38051832

RESUMO

BACKGROUND: Repairing the epidermal barrier is critically important in atopic dermatitis (AD), but the effect of moisturizer on quality of life (QOL) is not well characterized.  Objective: To assess whether the use of a moisturizer improves QOL in atopic patients with xerosis.  Methods: Thirty-five (35) adults with xerosis and AD received a moisturizer designed for AD to apply daily for three months. Adherence was assessed with electronic monitors. Quality of life (QOL) was assessed with the Dermatology Life Quality Index (DLQI) at baseline and follow-up.  Results: Mean adherence to the moisturizer was 46%. Dryness improved from 1.9 at baseline to 1.4 at follow-up (P=0.02). DLQI improved from 3.3 at baseline to 1.5 at 3 months (P=0.005). The "feeling self-conscious or embarrassed due to their skin condition" DLQI item improved from 0.79 at baseline to 0.14 at 3 months (P=0.0009).  Conclusion: Moisturizers are the foundation of AD treatment. Even non-medicated topical emollients can improve QOL in patients with AD.  J Drugs Dermatol. 2023;22(12):e51-e52.     doi:10.36849/JDD.7036e.


Assuntos
Dermatite Atópica , Gastroenteropatias , Adulto , Humanos , Qualidade de Vida , Emolientes , Dermatite Atópica/diagnóstico , Dermatite Atópica/tratamento farmacológico , Epiderme , Gravidade do Paciente , Índice de Gravidade de Doença , Resultado do Tratamento
2.
J Drugs Dermatol ; 22(10): 1063-1064, 2023 Oct 01.
Artigo em Inglês | MEDLINE | ID: mdl-37801528

RESUMO

Rosacea has variable clinical presentation consisting of four overlapping phenotypes: erythematotelangiectatic, papulopustular, phymatous, and ocular.1 Rosacea's pathogenesis involves increased cutaneous density of Demodex folliculorum mites, which drive inflammation through activation of Toll-like receptor-2.1,2 Thus, topical ivermectin (IVM) 1.0% cream's anti-inflammatory and acaricidal activity provides an effective and targeted treatment for moderate-to-severe rosacea. However, literature assessing IVM is limited to efficacy in treating the papulopustular presentation, limiting generalizability.1,3,4 Although our primary endpoint was to assess patient adherence, the objective of this secondary analysis was to assess IVM efficacy in rosacea, regardless of clinical presentation.


Assuntos
Ivermectina , Rosácea , Humanos , Ivermectina/uso terapêutico , Rosácea/diagnóstico , Rosácea/tratamento farmacológico , Rosácea/patologia , Pele/patologia , Administração Cutânea , Anti-Inflamatórios/uso terapêutico
3.
J Drugs Dermatol ; 22(8): 838-839, 2023 08 01.
Artigo em Inglês | MEDLINE | ID: mdl-37556519

RESUMO

Improved patient-physician relationships (PPR) are associated with better patient satisfaction and disease outcomes, however, there is limited literature assessing how PPR affects adherence in dermatology. We recruited 30 subjects with a clinical diagnosis of rosacea. Subjects were instructed to use ivermectin 1% cream once daily for 3 months and adherence was measured using the Medication Event Monitoring System cap. The Patient-Doctor Relationship Questionnaire (PDRQ-9), a validated questionnaire assessing patients’ perceived strength of the relationship with their doctor, was completed. Mean adherence for all subjects over three months of the study was 62%. PDRQ-9 scores positively correlated with adherence rates for 3 months of treatment (r(26)=0.52; P=0.006). The perceived strength of the PPR may have a role in patients’ adherence to their medications. Improving the PPR, through empathy and effective communication, may facilitate better medication adherence and treatment outcomes. Perche PO, Singh R, Cook MK, et al. The patient-physician relationship and adherence: observations from a clinical study. J Drugs Dermatol. 2023;22(8):838-839. doi:10.36849/JDD.7103.


Assuntos
Médicos , Rosácea , Humanos , Rosácea/tratamento farmacológico , Resultado do Tratamento , Satisfação do Paciente , Ivermectina , Adesão à Medicação
4.
Antibiotics (Basel) ; 12(2)2023 Jan 28.
Artigo em Inglês | MEDLINE | ID: mdl-36830180

RESUMO

Acne vulgaris is the most common reason for pediatric patients and third most common reason for adult patients to seek care from a dermatologist in the US. However, referring providers may be reluctant to initiate patients on acne treatment or certain prescriptions. We assessed over-the-counter (OTC) and prescription acne (antibiotic and non-antibiotic) treatment rates to characterize differences by patient demographics and provider specialty. The National Ambulatory Medical Care Survey (NAMCS) was analyzed for all acne therapies prescribed for at least 10 unweighted visits between 1993 and 2016 (most recent years available). Prescription rates varied by age, with younger patients more likely to receive a prescription; insurance status, with privately insured patients more likely to receive a prescription; and across and within specialties, with dermatologists more likely to recommend a prescription medication than family medicine and pediatric providers. Among all forms of antibiotics for acne vulgaris, oral minocycline was the most commonly prescribed antibiotic by dermatologists, followed by oral doxycycline. Oral minocycline was also the most common antibiotic prescribed by family physicians, followed by oral doxycycline and oral clindamycin, respectively. Pediatricians appeared to be less likely to prescribe oral antibiotics for acne. The OTC topical antimicrobial benzoyl peroxide was the most utilized drug for acne among pediatricians, and it was also the most commonly recommended OTC drug for acne among dermatologists, family physicians, and pediatricians.

5.
Cureus ; 15(1): e34141, 2023 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-36843714

RESUMO

The coronavirus disease 2019 (COVID-19) pandemic raised many challenges for dermatology. Safety is a principal concern for many patients, particularly those on medications that affect the immune system. Understanding how the pandemic affects patients' treatment adherence may be informative for counseling or other interventions to assure that treatment plans are not inappropriately interrupted, or for future pandemics. The purpose of this review was to investigate the extent to which the COVID-19 pandemic affected medication adherence in dermatology. A literature search of PubMed was performed using the search terms: adherence, compliance, dermatology, COVID-19, SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), and pandemic. Eleven primary research studies met the inclusion criteria and were included in the review. During the COVID-19 pandemic, non-adherence in dermatology patients was primarily linked to concern about the risk of COVID-19 infection with long-term use of immunomodulatory and immunosuppressive medications. In some cases, non-adherence was associated with feelings of depression, anxiety, or perceived stress. High adherence was attributed to regular and convenient communication between patients and dermatology providers through the effective use of telemedicine and electronic messaging. Frequent communication with providers to address patient concerns and provide continuity of care improved adherence. An integrated virtual approach to patient care facilitated this, particularly through the use of telemedicine. Implementation of routine virtual questionnaires was, to some extent, effective in replacing limited in-person patient-provider interactions during the pandemic. Finally, the added threat of the pandemic presented an additional mental health component to consider for patients, supporting the need for a multidisciplinary approach to patient care.

6.
Pediatr Dermatol ; 40(4): 743-746, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-36815604

RESUMO

Social media (SM) use has accelerated at an unprecedented pace and dermatology literature evaluating SM use is primarily centered on the quality and quantity of dermatologic content, with minimal research on how adolescent patients experience such content. We recruited 15 patients between the ages of 13-18 years from the Atrium Health Wake Forest Baptist Department of Dermatology to interview regarding their experience with dermatologic content on SM. Despite most participants' insightful comments on SM use and the relative lack of dermatologic content validation on SM, many participants adopted skin care advice from SM. Adolescents are particularly vulnerable to social influence and it is important dermatologists understand how pervasive skin-related content is on these platforms.


Assuntos
Dermatologia , Mídias Sociais , Humanos , Adolescente
7.
Arch Dermatol Res ; 315(6): 1809-1811, 2023 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-36652005

RESUMO

Patient adherence to medications usually increases with age, however, it can also be impacted by other factors. Accountability is a psychosocial construct that is defined as the expectation for an individual to account for their actions. Accountability may also influence patients' motivation to adhere to their treatments. We assessed the relationship between age and perception of accountability as well as efficacy of interventions to improve accountability in a clinical study of 30 rosacea patients. Accountability was assessed using the validated Accountability Measurement Tool. Interventions to improve accountability included a digital interaction group and a digital skin analysis group. All patients were given ivermectin cream 1% and informed to apply it daily for 3-months. There was a negative association between age and AMT scores in all intervention groups, including the control group. Younger patients have a baseline greater perception of accountability that responded more to our interventions.


Assuntos
Rosácea , Humanos , Rosácea/tratamento farmacológico , Ivermectina/uso terapêutico , Administração Cutânea , Creme para a Pele , Percepção
9.
Ann Pharmacother ; 57(1): 86-98, 2023 01.
Artigo em Inglês | MEDLINE | ID: mdl-35587593

RESUMO

OBJECTIVE: The objective of this article is to review abrocitinib, an oral Janus kinase (JAK) 1 inhibitor, for the treatment of patients with moderate-to-severe atopic dermatitis (AD). DATA SOURCES: A literature search of MEDLINE (PubMed) was performed for articles from inception through end-March 2022 using the following search terms: atopic dermatitis, abrocitinib, PF-04965842, methotrexate, cyclosporine, dupilumab, ruxolitinib, and JAK-STAT pathway. STUDY SELECTION AND DATA EXTRACTION: English articles relating to pharmacology, pharmacokinetics, efficacy, and safety of abrocitinib, and other conventional systemic medications for AD, were included. DATA SYNTHESIS: Across phase IIb and phase III clinical trials, abrocitinib was efficacious with an average of 47.5% patients on 200 mg abrocitinib and 32.0% on 100 mg abrocitinib achieving an Investigator's Global Assessment (IGA) of 0 or 1 at 12 weeks. In comparison with dupilumab 300 mg subcutaneously every other week, patients on abrocitinib 200 mg once daily had improved disease severity and itch response. The majority of adverse events were not severe and self-limited. RELEVANCE TO PATIENT CARE AND CLINICAL PRACTICE: Prior to Food and Drug Administration (FDA) approval of abrocitinib, prednisone was the only FDA-approved oral medication for AD. Although biologics such as dupilumab have revolutionized care, some patients prefer oral medications. Compared with clinical trials of conventional AD treatments, abrocitinib appears more effective. CONCLUSIONS: Abrocitinib is an efficacious oral JAK 1 inhibitor recently FDA-approved for patients ≥ 18 years old with moderate-to-severe AD who have not responded to systemic medications or when contraindicated otherwise.


Assuntos
Produtos Biológicos , Ciclosporinas , Dermatite Atópica , Humanos , Adolescente , Dermatite Atópica/tratamento farmacológico , Prednisona/uso terapêutico , Metotrexato/uso terapêutico , Janus Quinases/uso terapêutico , Resultado do Tratamento , Método Duplo-Cego , Fatores de Transcrição STAT/uso terapêutico , Transdução de Sinais , Índice de Gravidade de Doença , Produtos Biológicos/uso terapêutico , Ciclosporinas/uso terapêutico , Imunoglobulina A/uso terapêutico
11.
J Drugs Dermatol ; 21(12): 1366-1368, 2022 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-36468955

RESUMO

BACKGROUND: In the last several years, oral tofacitinib has become an increasingly utilized off-label treatment option for immune-mediated skin conditions such as alopecia areata (AA), vitiligo, plaque psoriasis, and atopic dermatitis. Few case reports exist of patients with concomitant AA and vitiligo treated with tofacitinib. METHODS: Photographs of the patient's affected disease areas were obtained at initiation of tofacitinib 5 mg twice daily (BID) and subsequent return visits over two years of treatment. A PubMed search for case reports and other relevant literature was performed using the keywords: alopecia areata, vitiligo, and tofacitinib. RESULTS: Two case reports in the literature describe patients with concomitant AA and vitiligo who were treated with tofacitinib. Both cases use adjuvant therapy or continued therapy, in addition to oral tofacitinib. Our patient was treated with low-dose tofacitinib monotherapy and had marked improvement in her AA and vitiligo, with moderate re-pigmentation of her hands and regrowth of the scalp and eyebrows within several months of treatment. Treatment effects continued to improve over two years without noted adverse effects. CONCLUSION: Tofacitinib 5 mg BID monotherapy was an efficacious and well-tolerated treatment option for a patient with refractory alopecia areata and vitiligo. J Drugs Dermatol. 2022;21(12):1366-1368. doi:10.36849/JDD.6826.


Assuntos
Alopecia em Áreas , Vitiligo , Humanos , Feminino , Alopecia em Áreas/diagnóstico , Alopecia em Áreas/tratamento farmacológico , Vitiligo/complicações , Vitiligo/diagnóstico , Vitiligo/tratamento farmacológico , Pirróis/uso terapêutico
12.
J Drugs Dermatol ; 21(11): 1191-1195, 2022 Nov 01.
Artigo em Inglês | MEDLINE | ID: mdl-36342733

RESUMO

The associated direct and indirect costs of acquiring acne vulgaris (acne) treatment from a clinician may prohibit some patients from doing so. Barriers to care may also influence patient preferences for treatment, and while both over-the-counter (OTC) and prescription acne treatments are efficacious, preferences for OTC or prescription acne medications are not well established. We recruited 529 adult subjects from the United States through Amazon Mechanical Turk (MTurk), and subjects were surveyed about acne, their acne treatment preferences, and any barriers to care. A total of 450 subjects passed the attention check and were included in the analysis. Of respondents who had tried both OTC and prescription treatments (n=223), more respondents reported that they preferred prescription treatments (130/223, 58.3%), compared with OTC treatments (64/223, 28.7%); or no preference (29/223, 13.0%; P=0.00001). Almost half of all respondents also stated that they experienced barriers to accessing medical care for acne treatment (192/450 42.7%); cost and transportation were the top 2 factors. Considering how common barriers are, and their everchanging nature, some patients may benefit from a discussion of alternative non-prescription acne treatments, serving as a bridge to therapy or while patients are unable to reach a medical provider. J Drugs Dermatol. 2022;21(11):1191-1195. doi:10.36849/JDD.6940.


Assuntos
Acne Vulgar , Medicamentos sob Prescrição , Adulto , Humanos , Estados Unidos , Preferência do Paciente , Acne Vulgar/diagnóstico , Acne Vulgar/tratamento farmacológico , Medicamentos sem Prescrição/uso terapêutico , Inquéritos e Questionários , Acessibilidade aos Serviços de Saúde , Resultado do Tratamento
13.
Dermatol Ther ; 35(11): e15849, 2022 11.
Artigo em Inglês | MEDLINE | ID: mdl-36131640

RESUMO

Atopic dermatitis (AD) is a common relapsing inflammatory skin condition associated with a high economic burden due to its chronicity and multitude of direct and indirect treatment costs. AD disproportionately impacts children and minority populations, and treatment choices are cost-prohibitive for many patients. Our objective was to describe the treatment and management of AD from a cost-conscious perspective. A review of the literature was conducted with PubMed using the following keywords: AD, cost, medications, treatment, management, efficacy, adherence, education, and prophylactic. The use of moisturizers prophylactically in high-risk infants who have yet to develop AD may reduce incidence of disease and associated costs. Increasing patient medication adherence and moisturizing between flares also reduces costs in AD. The use of corticosteroids as the first-line treatment is efficacious and cost-effective for mild cases of AD, however, in severe cases of AD corticosteroids alone are not sufficient. Systemic biologics are necessary in some patients with severe cases of AD; however, they are associated with high costs. Phototherapy, through portable home units, tanning beds, and natural sunlight are cost-effective alternatives. Effective management of AD improves with education programs for both the patient and their family, reducing long-term costs in the management of this disease. Reducing AD treatment costs requires consideration of prophylactic therapies, patient education, and should differ based on the severity of disease. A multifaceted approach to AD treatment reduces costs and health-care barriers.


Assuntos
Dermatite Atópica , Criança , Lactente , Humanos , Dermatite Atópica/tratamento farmacológico , Dermatite Atópica/epidemiologia , Custos de Cuidados de Saúde , Análise Custo-Benefício , Pele , Incidência
14.
J Drugs Dermatol ; 21(7): 758-764, 2022 Jul 01.
Artigo em Inglês | MEDLINE | ID: mdl-35816068

RESUMO

BACKGROUND: The chronicity of acne and its treatment with topicals contribute to poor treatment adherence and persistence. How well newly diagnosed acne patients use their treatment is not well characterized. Adherence refers to patients obtaining treatment and acting in accordance with a prescribed interval and dose; persistence is the duration of time patients continue on treatment. OBJECTIVE: To assess adherence and persistence to acne medications in newly diagnosed acne patients. METHODS: Truven Health MarketScan® Databases were utilized to assess United States claims data between 2008 to 2011 for newly diagnosed acne patients using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) 706.1 code. RESULTS: Among 230,552 males and females age ≥ 12 who filled an index medication within 1 year of acne diagnosis, Medication Possession Ratio was ≥ 0.8 in 70.3% of patients, and persistence was 1.85% at 12 months. LIMITATIONS: Adherence of patients given multiple products may be even worse than for patients given a single medication. CONCLUSIONS: While Medication Possession Ratio, was high, persistence to initial acne medication was poor. Though patients may have their medications, they are not necessarily using them. Enhancing patients’ use of their treatment may be critical to improving patients’ long-term treatment outcomes. J Drugs Dermatol. 2022;21(7):758-764. doi:10.36849/JDD.6832.


Assuntos
Acne Vulgar , Adesão à Medicação , Acne Vulgar/diagnóstico , Acne Vulgar/tratamento farmacológico , Bases de Dados Factuais , Feminino , Humanos , Lactente , Masculino , Estudos Retrospectivos , Estados Unidos
16.
Clin Cosmet Investig Dermatol ; 15: 1037-1043, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35685998

RESUMO

Atopic dermatitis (AD) is a chronic inflammatory skin disease that greatly impacts patient quality of life. Type 2 cytokine interleukin (IL)-13 is integral to the pathogenesis of AD. Tralokinumab is a fully human IgG4 monoclonal antibody that specifically targets IL-13, preventing downstream signaling of inflammatory pathways that may contribute to AD. Tralokinumab was US Food and Drug administration (FDA) recently approved for the treatment of moderate to severe AD on December 28, 2021. In our review, we will explore the efficacy and adverse effects (AEs) of tralokinumab for the treatment of patients with moderate to severe AD. A PubMed search for key articles on the emerging clinical data of tralokinumab was performed. Six randomized controlled trials of tralokinumab identified improvements in disease severity measures, including Investigator's Global Assessment (IGA) scores and Eczema Area Severity Index 75 (EASI75) scores. Four of these studies demonstrated improvements in quality of life measures with tralokinumab, including pruritus scores, sleep interference scores, Dermatology Life Quality Index, SCORing Atopic Dermatitis (SCORAD), Patient Oriented Eczema Measure, and The Short Form 36 Health Survey (SF-36v2) scores. One study identified a similar immune response in patients taking tralokinumab to those taking the Tdap and meningococcal vaccines. Upper respiratory infection, conjunctivitis, and headaches were the most common adverse events. The varying criteria to assess changes in AD disease severity across different studies is a limitation of this review. Tralokinumab is another promising biologic option for the treatment of moderate to severe AD, which may reduce disease burden and improve patient quality of life.

17.
J Drugs Dermatol ; 21(6): 683-686, 2022 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-35674761

RESUMO

BACKGROUND: Recent changes to the iPLEDGE platform left providers without the ability to prescribe isotretinoin to their patients. A potential substitute for isotretinoin could be beneficial when the drug is unavailable. Prior to the FDA approval of isotretinoin, a vitamin A derivative, vitamin A was studied for its use in acne management. OBJECTIVE: To review the potential of vitamin A to serve as a substitute for isotretinoin when the latter drug is inaccessible. METHODS: We conducted a review of published literature from 1931 to 2021, regarding the use of vitamin A in acne treatment, using PubMed and Google Scholar databases. Nine studies were selected after reviewing articles for relevancy to our topic. RESULTS: Eight out of the 9 studies noted improvement in patients’ acne with vitamin A use. Ranges of doses used were 36,000 I/U daily to 500,000 I/U daily, with 100,000 I/U daily being the most common. Side effects were mainly mucocutaneous in nature. LIMITATIONS: Many of the trials included in our review were published over 50 years prior and lack standardized components of clinical trials today. CONCLUSION: Oral vitamin A could potentially serve as a substitute for isotretinoin in acne management for select patients. However, due to its teratogenicity, potential for toxicity, and long half-life, strict monitoring under the care of a medical provider is prudent. Since vitamin A is available without a prescription, strict monitoring cannot be assured, and especially careful patient selection and education would be essential. J Drugs Dermatol. 2022;21(6):683-686. doi:10.36849/JDD.6781.


Assuntos
Acne Vulgar , Fármacos Dermatológicos , Acne Vulgar/induzido quimicamente , Acne Vulgar/diagnóstico , Acne Vulgar/tratamento farmacológico , Administração Oral , Humanos , Isotretinoína , Vitamina A/efeitos adversos
18.
Cureus ; 14(5): e25292, 2022 May.
Artigo em Inglês | MEDLINE | ID: mdl-35637919

RESUMO

Hidradenitis suppurativa (HS) can severely impact patients' quality of life. However, its specific impact on participation in everyday social activities is not well characterized. We recruited a cohort of patients with HS to complete a survey assessing the degree of interference HS has on participation in social activities. Patients also completed the Brief Fear of Negative Evaluation (BFNE) to assess levels of social anxiety. The majority of patients in our cohort, regardless of Hurley Stage, reported interference with social activities, and patients with more painful nodules and greater body region involvement reported greater interference with social activities. BFNE scores were high in our cohort, and patients with higher BFNE scores reported greater interference in all social activities assessed. Both the physical and psychological effects of HS may interfere with patients' participation in social activities, and efforts to treat both aspects may improve quality of life.

19.
Clin Exp Dermatol ; 47(10): 1853-1856, 2022 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-35546559

RESUMO

Full-body skin examinations (FBSEs) involve examination of the patient's skin from head to toe, and may be uncomfortable for some patients. While many patients prefer same-sex providers for pelvic, genital and rectal exams, desire for same-sex providers for FBSEs is not well characterized. This may be further magnified when FBSE is performed by medical trainees. We surveyed 566 subjects using Amazon Mechanical Turk (AMT), an online crowdsourcing platform, to assess the public's willingness to receive FBSEs based on the sex and/or gender and the level of training of the healthcare provider (HCP). The overall willingness by all respondents to undergo FBSE performed by a dermatologist, dermatology resident and medical student was 84.3%, 77.5% and 65.7%, respectively, if the HCP was the same sex/gender, compared with 60.6%, 54.8% and 45.7% if the HCP was a different sex/gender (P < 0.001). In our cohort, unwillingness for FBSEs was greater if the patient was female, if the HCP was a different gender/sex from the patient and if the HCP was a medical student.


Assuntos
Neoplasias Cutâneas , Estudantes de Medicina , Feminino , Humanos , Exame Físico , Pele , Neoplasias Cutâneas/diagnóstico , Inquéritos e Questionários
20.
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...